Welcome to our dedicated page for BioAge Labs SEC filings (Ticker: BIOA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioAge Labs, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutic candidates tied to human aging biology. The company's 8-K reports record periodic financial results, Regulation FD clinical updates for BGE-102, and disclosure of NLRP3 and APJ program development.
Other filings describe capital actions and governance, including common stock offering agreements under shelf registration statements, use-of-proceeds categories for research, clinical development, manufacturing and general corporate purposes, annual meeting proxy matters, director elections, auditor ratification, and board recommendations. These records also frame the company's capital structure and public-company reporting obligations.
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of BioAge Labs, Inc. common stock on an amended Schedule 13G. They collectively report beneficial ownership of 2,390,605 shares of common stock, representing 5.38% of the class.
All 2,390,605 shares are reported with shared voting power and shared dispositive power, with no sole voting or dispositive power. The percentage is calculated using 44,452,734 shares of BioAge Labs common stock outstanding as of May 1, 2026, as disclosed in the company’s Quarterly Report for the period ended March 31, 2026.
BioAge Labs is a clinical-stage biopharmaceutical company focused on cardiometabolic diseases driven by aging biology. For the three months ended June 30, 2026, it generated $2.5 million in collaboration revenue and reported a net loss of $26.1 million, or $0.58 per share. For the first six months of 2026, collaboration revenue was $5.2 million and the net loss was $48.4 million.
Research and development expenses for the six-month period rose to $44.8 million, driven mainly by lead candidate BGE-102, including completion of a Phase 1 trial, initiation of the QUELL-CV Phase 2 study and preparations for the QUELL-DME ophthalmology trial. General and administrative expenses were $15.2 million.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $381.3 million, with stockholders’ equity of $374.9 million and no term loan debt outstanding. Management states this capital is expected to fund operations and capital expenditures through 2029 while advancing BGE-102, APJ obesity programs and collaborations with Novartis and Eli Lilly.
BioAge Labs, Inc. reported collaboration revenue of $2.4 million for the quarter ended June 30, 2026, unchanged from the prior-year period. Research and development expenses rose to $24.4 million, mainly from higher spending on lead NLRP3 inhibitor BGE-102, including the Phase 2 QUELL-CV trial and planned QUELL-DME study, while general and administrative expenses were $7.4 million. Net loss was $26.1 million, or $0.58 per share.
As of June 30, 2026, BioAge held approximately $381.3 million in cash, cash equivalents and marketable securities and expects this to fund operations and capital expenses through 2029. The company dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 in about 160 adults with obesity and elevated inflammation, and plans to start QUELL-DME, a Phase 1b/2a trial in diabetic macular edema, in mid-2026. BioAge also continues its APJ agonist obesity program and multi-year discovery collaborations with Novartis and Lilly ExploR&D.
BioAge Labs, Inc. principal accounting officer Shane Barton exercised stock options and sold shares of common stock in late June. He exercised options covering 59,934 shares at strike prices between $4.30 and $10.85 per share, then sold a total of 62,566 shares in open-market transactions at weighted average prices around $25 per share. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and after these trades he reported holding no shares of common stock directly.
BIOA filed a Form 144 reporting proposed sale activity related to a stock option exercise. The filing lists a planned sale tied to a stock option exercise on 06/30/2026 and records 42,350 shares sold on 06/29/2026 for $1,067,577.87. The broker named is Fidelity Brokerage Services LLC.
BIOA submitted a notice under Section 144 relating to proposed sales of Common stock. The excerpt lists transactions dated 09/26/2024 ("IPO Shares", quantity 2,632) and 06/29/2026 ("Stock Option Exercise", quantity 39,718). The filing lists a broker-dealer Fidelity Brokerage Services LLC and shows values including 1,067,577.56 and a figure 44,452,734.
BioAge Labs, Inc. director Vijay Satyanand Pande received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and expire on June 9, 2036, bringing his directly held option position reported here to 22,000 shares. The entire award vests on the earlier of the next annual stockholder meeting or one year from the grant date, if he continues serving the company.
BioAge Labs, Inc. director Rekha Hemrajani received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and expire on June 9, 2036. The entire award will vest on the earlier of the company’s next annual stockholder meeting or one year from the grant date, subject to her continued service. Following this grant, she holds options for 22,000 shares directly.
BioAge Labs, Inc. director James Healy received a grant of stock options tied to the company’s common stock. The award covers 22,000 options with an exercise price of $15.48 per share and expires on June 9, 2036.
According to the terms, the entire option award will vest on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, provided Healy continues to serve the company through the applicable vesting date. After this grant, he holds 22,000 derivative securities directly.
BioAge Labs, Inc. director Patrick G. Enright received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $15.48 per share and were awarded as compensation rather than purchased in the open market.
These options vest in full on the earlier of the company’s next annual stockholder meeting or the one-year anniversary of the grant date, as long as Enright continues to serve the company through that vesting date. Following this grant, he holds 22,000 stock options directly.